Selected Publications
- Nopsopon T, Brown A, Hahn G, Rank M, Huybrechts KF, Akenroye A. Temporal variation in the effectiveness of biologics in asthma: Effect modification by changing patient characteristics. Respir Med. 2024 Sep 10;234:107802. PMID: 39260678.
- Akenroye A, Hvisdas C, Stern J, Jackson JW, Louisias M. Race and ethnicity, not just insurance, is associated with biologics initiation in asthma and related conditions. J Allergy Clin Immunol. 2024 Aug 6:S0091-6749(24)00780-2. PMID: 39116950.
- Nopsopon T, Chen Y, Chen Q, Wheelock CE, Weiss ST, McGeachie M, Lasky-Su J, Akenroye A. Untargeted metabolomic analysis reveals different metabolites associated with response to mepolizumab and omalizumab in asthma. ERJ Open Res. 2024 Aug 5;10(4):00931-2023. PMID: 39104961.
- Akenroye A, Marshall J, Simon AL, Hague C, Costa R, Jamal-Allial A, McMahill-Walraven CN, Haffenreffer K, Han A, Wu AC. Smaller differences in the comparative effectiveness of biologics in reducing asthma-related hospitalizations compared to overall exacerbations. J Allergy Clin Immunol Pract. 2024 Jun;12(6):1568-1574.e2. PMID: 38431251.
- Nopsopon T, Barrett NA, Phipatanakul W, Laidlaw TM, Weiss ST, Akenroye A. Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab. Allergy. 2024 May;79(5):1195-1207. PMID: 38164813.
- Akenroye A, Nopsopon T, Cho L, Moll M, Weiss ST. Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein-protein interaction analyses. Respir Res. 2023 Dec 06; 24(1):305. PMID: 38057814; PMCID: PMC10698971.
- Akenroye A, Segal J, Zhou G, et al. Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation. J Allergy Clin Immunol. 2023 May;151(5):1269-1276. PMID: 36740144.
- Chen ML, Nopsopon T, Akenroye A. Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract. 2023 May;11(5):1475-1484. PMID: 36716995.
- Nopsopon T, Lassiter G, Chen ML, Alexander GC, Keet C, Hong H, Akenroye A. Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. J Allergy Clin Immunol. 2023 Mar;151(3):747-755. PMID: 36538979.
- Akenroye A, Lassiter G, Jackson JW, Keet C, Segal J, Alexander GC, Hong H. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. J Allergy Clin Immunol. 2022 Nov;150(5):1097-1105.e12. PMID: 35772597.
- Akenroye A, Heyward J, Keet C, Alexander GC. Lower Use of Biologics for the Treatment of Asthma in Publicly-insured Individuals. J Allergy Clin Immunol Pract. 2021 Nov;9(11):3969-3976. PMID: 33556592.
- Hvisdas C, Louisias M, Laidlaw TM, Akenroye A. Addressing disparities in biologic drug development in the United States. J Allergy Clin Immunol. 2021 Nov;148(5):1154-1156. PMID: 34530019.
- Akenroye A, Keet C. Underrepresentation of blacks, smokers, and obese patients in studies of monoclonal antibodies for asthma. J Allergy Clin Immunol Pract. 2020 Feb;8(2):739-741.e6. PMID: 31472296.